

# VIM-2 beta-lactamase in *Pseudomonas aeruginosa* isolates from Zagreb, Croatia

---

Bošnjak, Zrinka; Bedenić, Branka; Mazzariol, Annarita; Jarža-Davila, Neda; Šuto, Sandra; Kalenić, Smilja

Source / Izvornik: **Scandinavian Journal of Infectious Diseases, 2010, 42, 193 - 197**

Journal article, Accepted version

Rad u časopisu, Završna verzija rukopisa prihvaćena za objavljivanje (postprint)

<https://doi.org/10.3109/00365540903426582>

Permanent link / Trajna poveznica: <https://urn.nsk.hr/urn:nbn:hr:105:875221>

Rights / Prava: [In copyright](#) / [Zaštićeno autorskim pravom.](#)

Download date / Datum preuzimanja: **2024-06-25**



Repository / Repozitorij:

[Dr Med - University of Zagreb School of Medicine  
Digital Repository](#)





## Središnja medicinska knjižnica

**Bošnjak Z., Bedenić B., Mazzariol A., Jarža-Davila N., Šuto S, Kalenić S.  
(2010) *VIM-2 beta-lactamase in Pseudomonas aeruginosa isolates  
from Zagreb, Croatia. Scandinavian Journal of Infectious Diseases, 42  
(3). pp. 193-7. ISSN 0036-5548***

<http://informahealthcare.com/journal/inf>

<http://dx.doi.org/10.3109/00365540903426582>

<http://medlib.mef.hr/1407>

University of Zagreb Medical School Repository

<http://medlib.mef.hr/>

1 VIM-2  $\beta$ -LACTAMASE IN *PSEUDOMONAS AERUGINOSA* ISOLATES FROM ZAGREB,  
2 CROATIA

3

4 Z. Bošnjak<sup>a</sup>, B. Bedenić<sup>a,b</sup>, A. Mazzariol<sup>c</sup>, N. Jarža-Davila<sup>d</sup>, S. Šuto<sup>d</sup>, S. Kalenić<sup>a,b</sup>

5 <sup>a</sup>Department of Clinical and Molecular Microbiology, Clinical Hospital Center Zagreb,  
6 Zagreb, Croatia

7 <sup>b</sup>School of Medicine, University of Zagreb, Zagreb, Croatia

8 <sup>c</sup>Department of Microbiology, Faculty of Medicine and Surgery, University of Verona,  
9 Verona, Italy,

10 <sup>d</sup>Department of Microbiology, Zagreb Institute of Public Health „A. Štampar“, Zagreb,  
11 Croatia

12

13 Correspondence: B. Bedenić, Department of Microbiology, School of Medicine, University of  
14 Zagreb, Zagreb, Croatia, tel: +385 1 2367304, fax: +385 1 4590 130, e-mail:

15 [branka.bedenic@zg.htnet.hr](mailto:branka.bedenic@zg.htnet.hr)

16

17

18 ABSTRACT

19 The aim of this investigation was to characterize MBLs in *P. aeruginosa* isolates from  
20 Zagreb, Croatia.

21 100 *P. aeruginosa* isolates with reduced susceptibility to either imipenem or meropenem were  
22 tested for the production of MBLs by E test MBL. The susceptibility to a wide range of  
23 antibiotics was determined by broth microdilution method. The presence of *bla*<sub>MBL</sub> genes was  
24 detected by PCR. Hydrolysis of 0.1 mM imipenem by crude enzyme preparations of  $\beta$ -  
25 lactamases was monitored by UV spectrophotometer.. Outer membrane proteins were  
26 prepared and analysed by SDS-PAGE.

27 Six out of 100 isolates were positive for MBLs by E test. All strains were resistant to  
28 gentamicin, ceftazidime and cefotaxime and all except of one to imipenem.

29 Six strains positive for MBLs in E test were identified as VIM MBLs producers by PCR.

30 Sequencing of *bla*<sub>VIM</sub> genes revealed the production of VIM-2  $\beta$  -lactamase in all six strains.

31 This investigation proved the occurrence of VIM-2  $\beta$ -lactamase among *P. aeruginosa* strains  
32 from Zagreb, Croatia. VIM-2  $\beta$  -lactamase with similar properties was previously described in  
33 another region of Croatia, Italy, France, Spain, Greece, Taiwan and South Korea suggesting  
34 that this type of enzyme is widespread in Mediteranean region of Europe and in Far East.

35 **Key words:** meropenem, imipenem, metallo- $\beta$ -lactamases, resistance, *Pseudomonas*  
36 *aeruginosa*

37 INTRODUCTION

38 Carbapenemases may be defined as  $\beta$ -lactamases that significantly hydrolyse at least  
39 imipenem or/and meropenem [1]. The most clinically significant carbapenemases belong to  
40 class B [2]. They are metallo- enzymes which require zinc as a cofactor and comprise four  
41 families: IMP, VIM, SPM, GIM and SIM [3-6]. The VIM-type enzymes appear to the most  
42 prevalent in Europe and Korea, and at least 10 different variants have been described [4]. The

43 worldwide spread of acquired metallo- $\beta$ -lactamases (MBLs) in gram-negative bacilli has  
44 become a great concern. MBLs possess a broad hydrolysis profile that includes carbapenems  
45 and almost all extended-spectrum  $\beta$ -lactams except of aztreonam. Carbapenem resistant  
46 strains of *P.aeruginosa* have been detected with increasing frequency in hospitals in Zagreb  
47 and pose serious therapeutic problem. The aim of this investigation was to characterize MBLs  
48 in *P. aeruginosa* isolates from Zagreb, Croatia.

49

## 50 MATERIALS AND METHODS

### 51 *Bacteria*

52 100 *P. aeruginosa* isolates with reduced susceptibility to either imipenem or meropenem were  
53 tested for the production of MBLs by E test MBL (Solna, Sweden). The strains were isolated  
54 during 2002 to 2004 at the Clinical Hospital Center Zagreb and University Hospital Merkur  
55 in Zagreb from various clinical specimens and wards (Table 1). Isolates were identified by  
56 conventional biochemical methods.

### 57 *E test MBL test*

58 The strip (AB Biodisk, Solna, Sweden) contains a double-sided seven-dilution range of  
59 imipenem (4 to 256 mg/L) and imipenem (1 to 64 mg/L) in combination with a fixed  
60 concentration of EDTA. An overnight culture of the test strains in Mueller-Hinton (MH) broth  
61 was diluted to match the turbidity of 0.5 McFarland, swabbed on the plates of MH agar and  
62 the plates were incubated at 35°C. A decrease of imipenem MIC by  $\geq 3$  twofold dilutions in  
63 the presence of EDTA was interpreted as being suggestive of MBL production [7].

### 64 *Susceptibility testing*

65 The susceptibility to a wide range of antibiotics was determined by twofold broth  
66 microdilution method in cation supplemented MH broth in 96 well microtiter plates according  
67 to CLSI [8]. The inoculum size was  $5 \times 10^5$  CFU/ml. The plates were incubated for 18 h at 37

68 °C. The strains with MICs below the resistance breakpoint were tested with higher inoculum  
69 of 10<sup>8</sup> CFU/ml as well. The test was performed in triplicate. *P. aeruginosa* ATCC 27853 was  
70 used for quality control. Antibiotic powders were obtained from the following manufacturers:  
71 ceftazidime, gentamicin and clavulanic acid-Pliva, Zagreb; cefotaxime-Belupo, Koprivnica;  
72 cefepime-Bristol Myers Squibb, Zagreb; imipenem-MSD, Zagreb; meropenem-AstraZeneca,  
73 Zagreb.

#### 74 *Enzyme characterization*

75 The bacterial cells were pelleted from exponential phase cultures in Lurian-Bentoni (LB)  
76 broth by centrifugation at 6000 g. The pellet was washed and resuspended in cation  
77 supplemented phosphate buffer (0.1 mM, pH 7). Enzymes were released by sonication in ice  
78 bath. Cell debris was removed by centrifugation at 10 000 g and supernatant was stored at -  
79 20°C as crude enzyme preparation. Hydrolysis of 0.1 mM imipenem by crude enzyme  
80 preparations of  $\beta$ -lactamases was monitored by UV spectrophotometer at 298 nm. The change  
81 of absorbance was recorded. Inhibition of enzyme activity was determined by 2 mM EDTA.  
82 Enzyme activity was expressed as nmol of substrate hydrolyzed per minute expressed  
83 relatively to the total protein content of the sample. Concentration of the protein in the  
84 samples was determined with a commercial method (BioRad).

#### 85 *Analytical isoelectric focusing (IEF)*

86 IEF was performed according to Matthew et al [9]. The organisms were grown overnight in  
87 BHI broth, collected by centrifugation and  $\beta$ -lactamases were extracted from bacteria by  
88 sonication. Cell debris was removed by centrifugation at 14 000 g. Supernatant was used as  
89 crude enzyme. Isoelectric focusing was performed on polyacrylamide gels (acrylamide 7%,  
90 bis-acrylamide 0.2%) containing ampholines with a pH range of 3.5 to 10. The  $\beta$ -lactamases  
91 were detected by staining of the gel with nitrocefin, following IEF.  $\beta$ -lactamases of known

92 pI (isoelectric point) were used as standards: TEM-1, TEM-2, SHV-1, SHV-2, SHV-4 and  
93 SHV-5.

94

#### 95 *Polymerase chain reaction and sequencing of bla<sub>VIM</sub> genes*

96 The presence of *bla<sub>VIM</sub>* and *bla<sub>IMP</sub>* genes was tested by PCR. Primers: VIM1F (5'-CAG-ATT-  
97 GCC-GAT-GGT-GGT-TGG-3') and VIM1R (5'-AGG-TGG-GCC-ATT-CAG-CCA-GA-3')  
98 were used to amplify *bla<sub>VIM</sub>* genes. whereas primers IMP-A (5-GAA-GGY-GTT-TAT-GTT-  
99 CAT-AC-3') and IMP-B (5'-GTA-MGT-TTC-AAG-AGT-GAT-GC-3') [1] were used for  
100 detection of *bla<sub>IMP</sub>* genes. The cycling conditions were as follows: 94°C-5min, and then 30  
101 cycles-94°C-1 min, 55°C-1 min, 72°C-1-min and final extension at 72°C for 5 min. PCR  
102 products were subjected to electrophoresis in agarose gel at 100 V. PCR products were  
103 detected under UV light after staining with etidium bromide.

104 The amplicons were sequenced from both sides.

#### 105 *Plasmid analysis*

106 Plasmids were extracted by alkaline lysis method as described previously [10]. Overnight  
107 cultures of the test strains in LB broth (12 ml) were centrifuged at 14 000 rpm and the pellet  
108 was resuspended in Solution I (25 mM Tris Hcl (pH 8), 50 mM Glucose, 10 mM EDTA (pH  
109 8) containing 5 mg/ml lysozyme and 10 mg/ml RNA-se. The suspensions were mixed and  
110 incubated on ice for 10 min before addition of the Solution II (0.2 N NaOH, 1% SDS). The  
111 samples were then mixed gently by inversion of the tubes. After incubation on ice for 15 min,  
112 Solution III was added (3 M K-Ac, pH 4.8). Solution III contained 120 ml 5 M K-Ac, 23 ml  
113 glacial acetic acid and 57 ml H<sub>2</sub>O. Samples were again mixed by inversion of the tubes,  
114 incubated on ice for 15 min and centrifuged for 15 min at 14 000 rpm at room temperature.  
115 The supernatant was transferred to the clean tube avoiding any floating precipitate. Equal  
116 volume of phenol/chlorophorm was added, samples were mixed and centrifuged for 5 min.

117 This step was repeated twice. The supernatant was transferred to the clean tube without  
118 touching the water /chlorophorm interface or the precipitate in this region and 0.6 volumes of  
119 isopropanol were added. The samples were incubated 30 min at room temperature and  
120 centrifuged at 14 000 rpm for 20 min. The supernatant was discarded and the pellet dried in  
121 the vacuum centrifuge. The pellet was washed once with 70% ethanol and resuspended in TE  
122 buffer. Samples were subjected to electrophoresis in 0.7 % agarose gel in TBE buffer. After  
123 staining with ethidium bromide, the DNA was visualised by ultraviolet light.

124

#### 125 *Genotyping of strains by pulsed-field gel electrophoresis*

126 Isolation of chromosomal DNA was performed as described by Kaufman et al [11]. For each  
127 isolate 1,0 ml (optical suspension density 0,6-0,7 at 540 nm) of an overnight culture grown in  
128 BHI broth was pelleted by centrifugation at 10 000 rpm for 2 min. After being washed in 1 ml  
129 SE buffer (75mM NaCl;25mM EDTA, *Sigma*), bacteria were resuspended in 500µl SE buffer  
130 with 10 µl lysosime (*Boehringer Mannheim GmbH*). Next, 500 µl of this bacterial suspension  
131 was mixed with 500 µl 2,0% low- melting-temperature agarose (InCert agarose; FMC  
132 Bioproducts) and left to solidify. Solid agarose plugs were then incubated for 24h at 56<sup>0</sup> C in  
133 2ml of ESP buffer (1% N-lauril sarcosine; 0,5 M EDTANa<sub>2</sub>, pH 9,5; 500 µg/ml proteinase K,  
134 *Sigma*). After 24h, the plugs were incubated at room temperature for 2 h in PMSF  
135 (phenylmethanesulfonyl-fluoride, *Aldrich*) and then washed three times for 30 min at 4<sup>0</sup> C  
136 with TE buffer (10mM Tris-Hcl,pH 8, 0,1 mM EDTA, *Sigma*) before macrorestriction with  
137 10U / 1 µl *Xba*I for 3 h at 37<sup>0</sup> C. Restriction fragments of DNA were separated by PFGE with  
138 a CHEF-DRIII apparatus (Bio-Rad Laboratories) through 1% pulsed-field certified agarose  
139 (*Bio-Rad*) at a field strength of 6 V/cm for 20 h at 11<sup>0</sup> C; with pulses from 5 to 50 -s in 0,5  
140 TBE buffer with thiurea (50mM, *Sigma*). A lambda ladder (*Roche*) was used as the molecular  
141 size marker. After electrophoresis, gels were stained with ethidium bromide, rinsed, and



142 photographed under UV light. The PFGE patterns were compared following the criteria of  
143 Tenover and colleagues for bacterial strain typing [12] and analysed by computer software  
144 (*GelComparII*). The patterns obtained were compared by clustering methods (unweighted  
145 pairgroup method with arithmetic averages) using the *Dice* coefficient. An optimization of  
146 0,50% and position tolerance of 3,00% were applied during the comparison of PFGE  
147 fingerprinting patterns.

148

#### 149 *Characterization of outer membrane proteins*

150 Outer membrane proteins of six MBL positive *P. aeruginosa* strains were prepared as  
151 described previously [13]. Cells were harvested from overnight cultures in LB broth and  
152 resuspended in phosphate buffer. Proteins were released from the cells by sonication in ice  
153 bath and collected by centrifugation at 10 000 g. After solubilization in 10 mM Tris HCl , 5  
154 mM MgCl<sub>2</sub> and to 2% sodium lauroyl sarconisate for for 1 h at 37°C the insoluble OMPs  
155 were recovered at 14 000 g. A second solubilization step was performed and the OMPs were  
156 again pelleted as above. Prior to SDS PAGE, the OMPs were denatured by the addition of  
157 3% SDS-5% β-mercaptoethanol and boiled for 10 min. Laemmli's sample buffer (62.5 mM  
158 Tris/Hcl, 2% SDS, 10% glycerol, 5% mercaptoethanol) and electrode buffer (25 mM Tris (pH  
159 8.3), 190 mM glycine, 0.1% SDS) were used.

160 Electrophoretic analysis of *P. aeruginosa* OMPs was performed in polyacrylamide gel. The  
161 gel contained 11% acrylamide, 0.54% bisacrylamide plus 0.2% SDS in 0.375 M Tris/HCl (pH  
162 8.8). Gel was polymerised with 0.2% TEMED and 0.25% ammonium persulfate. Stacking gel  
163 contained 4% acrylamide, 0.1% bisacrylamide, 0.1% SDS in 0.125 M Tris /HCl (pH 6.8), and  
164 was polymerised as above. Staining was performed with 0.125% Coomassie brilliant blue  
165 R250 in 45% methanol, 10% acetic acid for about 30 min. Destaining was performed in 45%  
166 methanol, 10% acetic acid.

167

168 RESULTS

169 *E test*

170 Six out of 100 isolates were positive for MBLs by E test.

171 *Prevalence*

172 The prevalence of MBLs among carbapenem resistant isolates of *P. aeruginosa* was 6%.

173 *Susceptibility testing*

174 All strains were resistant to gentamicin, ceftazidime and cefotaxime. All except of strain  
175 (132) were resistant to imipenem. Strains 6, 12, 132 and 135 were resistant to ciprofloxacin,  
176 strains 12, 22, 35 and 135 to aztreonam, strains 6, 12, 22 and 135 to cefoperazon and strains  
177 22, 35 and 135 to cefepime. Resistance to piperacillin alone and combined with tazobactam  
178 was observed in only one strain (135).

179 *Enzyme characterization*

180 The enzyme activity ranged from 6 to 420 nmol/imipenem/min/mg of protein. Carbapenemase  
181 activity was almost completely inhibited by 2 mM EDTA. (Table 2) .

182 IEF revealed a band with the pI of 5.3 in all strains.

183 *Polymerase chain reaction and sequencing of bla<sub>VIM</sub> genes*

184 Six strains yielded an amplicon of 523 bp with primers specific for VIM β-lactamases.

185 Sequencing of *bla<sub>VIM</sub>* genes revealed the production of VIM-2 β-lactamase in all six strains  
186 (Fig. 1). No IMP MBLs producers were detected by PCR.

187 *Plasmid analysis*

188 No plasmid DNA was found.

189 *Pulsed field gel electrophoresis*

190 The strains showed distinct PFGE patterns and were not clonally related (Fig. 2).

191 *Characterization of outer membrane proteins*

192 Four of the tested strains lacked altered OmpD2 protein (Table 1).

193

194 DISCUSSION

195 This investigation proved the occurrence of VIM-2  $\beta$ -lactamase among *P. aeruginosa* strains  
196 from Zagreb, Croatia. VIM-2  $\beta$ -lactamase was previously reported from another region in  
197 Croatia [14] suggesting that there is a regional spread of this resistance determinant. VIM-2  $\beta$   
198 -lactamase with similar properties was previously described in Italy [15], France [16], Spain  
199 [17], Greece [18], Taiwan [19] and South Korea [20] suggesting that this type of enzyme is  
200 widespread in Mediterranean region of Europe and Far East. VIM-2 is the most prevalent  
201 MBL in Taiwan [21].

202 The fact that all strains displayed similar enzyme activities, but one strain (132) showed  
203 markedly lower carbapenem MIC than the others suggests that there are other resistance  
204 mechanisms involved in the strains with high carbapenem MIC such as loss of outer  
205 membrane proteins detected in four strains (6, 12, 22, 135) or efflux. The strain with low  
206 carbapenem MIC probably had higher permeability coefficient or less efficient efflux pump.  
207 However, the carbapenem MICs rose above the resistance breakpoint for the strain 132 when  
208 a higher inoculum which is more likely to occur in *in vivo* situation, was applied. It is possible  
209 that *in vivo* in the presence of a high inoculum, high level resistance arises. Little clinical  
210 information is available on the outcome of patients infected with carbapenem-susceptible  
211 MBL producing *P. aeruginosa*. There is no consensus on the interpretation and reporting of  
212 the antibiograms for the MBL producers. Four strains were resistant to aztreonam contrary to  
213 the results obtained from other authors [16-17,22]. Aztreonam is not hydrolyzed by MBLs [1]  
214 but resistance could be due to other mechanisms like overproduction of AmpC  $\beta$ -lactamase,  
215 coexistence of other  $\beta$ -lactamase or efflux as reported previously [23]. The macrorestriction of  
216 the Xba digested chromosomal DNA showed distinct patterns indicating that strains  
217 harbouring bla<sub>VIM</sub> genes are not clonally related. Thus it is more likely that the spread of MBL  
218 genes is due to the genetic exchange between different clones. The occurrence of MBLs was

219 sporadic. The strains were obtained from various wards in two hospitals during a wide time  
220 period.

221 Since all three attempts to transfer ceftazidime resistance to recipient strain and to isolate  
222 plasmid DNA were unsuccessful we can conclude that gene cassettes harbouring *bla*<sub>VIM</sub> genes  
223 were located in the integrons [20] which are inserted in the chromosome and that their  
224 dissemination in Croatia is due to the mobilization of the resistance genes.

225 Our strains harbouring VIM-2  $\beta$ -lactamase were resistant to all  $\beta$ -lactam antibiotics,  
226 aminoglycosides and fluoroquinolones and pose a serious therapeutic problem in our  
227 hospitals. The fact that all strains were resistant to gentamicin suggests that *bla*<sub>VIM</sub> genes are  
228 located on integrons containing gene cassettes with resistance determinants for  
229 aminoglycosides. Since most of the strains were resistant to aminoglycosides and  
230 fluoroquinolones as well only toxic compounds such as colistine are left to be administered as  
231 a therapeutic agent. The prevalence of MBL positive *P. aeruginosa* among our carbapenem  
232 resistant strains of this species is still low (6%) but there is a possibility of horizontal spread  
233 of *bla*<sub>VIM</sub> genes to *Enterobacteriaceae* which are more frequent pathogens. MBLs have  
234 already been found in the members of the family *Enterobacteriaceae* [18-19]. The difficulties  
235 in detecting MBLs producers in the routine laboratories together with the mobile nature of the  
236 gene cassettes carrying *bla*<sub>VIM</sub> genes facilitates their dissemination. Meropenem has been  
237 extensively used in our hospitals and the presence of MBLs among carbapenem resistant  
238 *P. aeruginosa* of different genotypes, isolated from different hospitals, although in low  
239 frequency, underscores the need for restricted use of carbapenems and their systematic  
240 surveillance. Constant and consistent surveillance of the MBL producing strains will be the  
241 prime measure to prevent their further dissemination.

242

243 REFERENCES

- 244 Nordmann P, Poirel L. Emerging carbapenemases in Gram-negative aerobes. Clin  
245 Microbiol Infect 2002;8:321-331.
- 246 Daiyasu H, Osaka K, Ishino Y, Toh H. Expansion of the zinc- metallo-hydrolase  
247 family of the  $\beta$ -lactamase fold. FEBS Letters 2001;503:1-6.
- 248 Cornaglia G, Riccio ML, Mazzarol A, Lauretti L, Fontana R, Rossolini GM.  
249 Appearance of IMP-1 metallo-  $\beta$ -lactamase in Europe. Lancet 1999; 353:899-900.
- 250 Lauretti L, Riccio ML, Mazzariol A, Cornaglia G, Amicosante G, Fontana R,  
251 Rossolini GM. Cloning and characterization of *bla*<sub>VIM</sub>, a new integron-borne metallo-  $\beta$ -  
252 lactamase gene from *Pseudomonas aeruginosa* clinical isolate. Antimicrob Agents Chemother  
253 1999; 43(7): 1584-1590.
- 254 Murphy TA, Simm AM, Toleman MA, Jones RN, Walsh T. Biochemical  
255 characterization of the acquired metallo- $\beta$ -lactamase SPM-1 from *Pseudomonas aeruginosa*.  
256 Antimicrobial Agents Chemother 2003;47(2):582-587.
- 257 Lee K, Yum JH, Yong D i sur. Novel aquired metallo- $\beta$ -lactamase gene, bla (SIM-1),  
258 in a class 1 integron from *Acinetobacter baumannii* clinical isolates from Korea. Antimicrob  
259 Agents Chemother 2005; 49: 4485-91.
- 260 Walsh TR, Bolmstrom A, Gales A. Evaluation of new E test for detecting metallo- $\beta$ -  
261 lactamases in routine clinical testing J Clin Microbiol 2002; 40:2755-2759.
- 262 Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial  
263 Susceptibility Testing; Eighteenth Informational Supplement, M100-S18. Wayne, PA: CLSI;  
264 2008.
- 265[9]. Matthew MA, Harris AM, Marshall MJ, Ross GW. The use of isoelectric focusing for  
266 detection and identification of  $\beta$ -lactamases. J Gen Microbiol 1975; 88:169-178.

- 267[10]. Birnboim HC, Doly J. A rapid alkaline extraction procedure for screening  
268 recombinant plasmid DNA. *Nucleic acid research* 1979;7(6):1513-23.
- 269[11]. Kaufman ME. Pulsed-Field Gel Electrophoresis. In: Woodford N, Johnsons A, eds.  
270 *Molecular bacteriology. Protocols and clinical applications*. New York; Humana Press Inc.  
271 Totowa, 1998: 33-51.
- 272[12]. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH,  
273 Swaminathan B. Interpretation of chromosomal DNA restriction patterns produced by pulsed-  
274 field gel electrophoresis; criteria for bacterial strain typing. *J Clin Microbiol* 1995;33:2233-  
275 2239.
- 276[13]. Hernandez-Alles S, Alberti S, Alvarez D, Domenech-Sanchez A, Martinez-Martinez  
277 L, Gil J Tomas JM, Benedi VJ. Porin expression in clinical isolates of *Klebsiella pneumoniae*.  
278 *Microbiology* 1999; 145:673-679.
- 279[14]. Sardelić S, Pallechi L, Punda-Polić V, Rossolini GM. Carbapenem resistant  
280 *Pseudomonas aeruginosa*-carrying VIM-2 metallo- $\beta$ -lactamase determinants, Croatia. *Emerg*  
281 *Infect Dis* 2003;9(8):1022-1023.
- 282[15]. Pallechi L, Riccio ML, Docquier JD, Fontana R, Rossolini GM. Molecular  
283 heterogeneity of bla(VIM-2)-containing integrons from *Pseudomonas aeruginosa* plasmids  
284 encoding VIM-2 metallo- $\beta$ -lactamase. *FEMS Microbiol Lett* 2001;195:145-150.
- 285[16]. Poirel L, Lambert T, Turkoglu S, Ronco E, Gaillard JL, Nordmann P. Characterization  
286 of class 1 integrons from *Pseudomonas aeruginosa* that contain the bla<sub>VIM-2</sub> carbapenem  
287 hydrolyzing  $\beta$  -lactamase and two novel aminoglycosides resistance gene cassettes.  
288 *Antimicrob Agents Chemother* 2001; 45:546-552.
- 289[17]. Prats G, Miro E, Mirelis B, Poirel L, Bellais S, Nordman P. First isolation of a  
290 carbapenem hydrolyzing  $\beta$  -lactamase in *Pseudomonas aeruginosa* in Spain. *Antimicrob*  
291 *Agents Chemother* 2002,46(3):932-933.

- 292[18]. Pournaras S, Maniati M, Petinaki E, Tzouvleleakis LS, Tsakris A, Legakis NJ, Maniatis  
293 AN. Hospital outbreak of multiple clones of *Pseudomonas aeruginosa* carrying the unrelated  
294 metallo-  $\beta$  -lactamase gene variants *bla*<sub>VIM-2</sub> and *bla*<sub>VIM-4</sub>. J Antimicrob Chemother  
295 2003;51:1409-1414.
- 296[19]. Yan JJ, Ko WC, Chuang CL, Wu JJ. Metallo-  $\beta$  -lactamase producing  
297 Enterobacteriaceae in a university hospital in Taiwan: prevalence of IMP-8 in *Enterobacter*  
298 *cloacae* and first identification of VIM-2 in *Citrobacter freundii*. J Antimicrob Chemother  
299 2002;50:503-511.
- 300[20]. Jeong SH, Lee K, Chong Y, Yum JH, Lee SG, Choi HJ, Kim JM, Han BH, Lee SW,  
301 Jeong TS. Characterization of a new integron containing VIM-2, a metallo-  $\beta$  -lactamase gene  
302 cassette, in a clinical isolate of *Enterobacter cloacae*. J Antimicrob Chemother 2003; 51:397-  
303 400.
- 304[21]. Yan JJ, Hsueh PR, Ko WC, Luh KT, Tsai SH, Wu HM, Wu JJ. Metallo-  $\beta$  -lactamase  
305 in clinical *Pseudomonas* isolates in Taiwan and identification of VIM-3, a novel variant of the  
306 VIM-2 enzyme. Antimicrob Agents Chemother 2001;45:2224-2228.
- 307[22]. Tsakris A, Tassios PT, Polydorou F, Malaka E, Antoniadis A, Legakis NJ. Infrequent  
308 detection of acquired metallo- $\beta$ -lactamases among carbapenem-resistant *Pseudomonas*  
309 isolates in a Greek hospital. Clin Microbiol Infect 2003;9:846-851.
- 310[23]. Galani I, Souli M, Chryssouli Z, Orlandou K, Giamerellou H. Characterization of a  
311 new integron containing *bla*<sub>VIM-1</sub> and aac(6')-IIc in an *Enterobacter cloacae* clinical isolate  
312 from Greece. J Antimicrob Chemother 2005;55:634-638.

Table1. Epidemiologic characteristics, minimum inhibitory concentrations (MIC) of various antibiotics against MBL positive *P. aeruginosa* strains and alteration of outer membrane proteins.

Strain No	Epidemiologic characteristics of <i>P. aeruginosa</i> strains						MIC (mg/L) <sup>1</sup>											Porins
	Specimen	Hospital <sup>2</sup>	Unit	PFGE type	Date of isolation (D/M/Y)	IMI	MEM	CAZ	CAZ/CL	CTX	CFP	FEP	AMT	PIP	TZP	GM	CIP	OMPD <sub>2</sub>
6	urine	A	nephrology	1	15/01/2004	>128	64	16	>128	>128	>128	16	8	64	32	>128	16	-
12	stool	A	haematology	2	14/01/2003	64	32	>128	>128	32	>128	16	>128	64	32	>128	64	-
22	Tracheal aspirate	A	Paediatric ICU	3	15/02/2003	>128	32	32	64	>128	16	64	>128	32	16	64	0.5	-
35	Wound swab	A	oncology	4	25/02/2003	>128	32	16	32	32	4	32	>128	64	32	>128	4	+
132	Tracheal aspirate	B	Surgery ICU	4	09/08/2003	16	8	>128	>128	64	4	16	0.12	32	8	16	32	+
135	Bronchal aspirate	B	Internal ICU	5	07/01/2002	>128	64	>128	>128	>128	>128	>128	>128	>128	>128	>128	>128	-

<sup>1</sup> Abbreviations-IMI-imipenem, MEM-meropenem, CAZ-ceftazidime, CAZ/CL-ceftazidime+clavulanic acid, CTX-cefotaxime, CFP-cefoperazone, FEP-cefepime, AMT-aztreonam, PIP-piperacillin, TZP-Tazobactam/piperacillin, GM-gentamicin, CIP-ciprofloxacin

<sup>2</sup> A- University Hospital Center-Zagreb, B-University Hospital Merkur



Table 2. Hydrolysis rates against imipenem of metallo- $\beta$ -lactamases produced by *P. aeruginosa* strains.

Strain No	Hydrolysis rate (nmol/min/mg protein)	Hydrolysis rate in the presence of 2 mM EDTA (nmol/min/mg protein)
6	$6 \times 10^{-9}$	$1 \times 10^{-13}$
12	$9 \times 10^{-9}$	$1.8 \times 10^{-11}$
22	$4.2 \times 10^{-8}$	$9.4 \times 10^{-12}$
35	$4 \times 10^{-8}$	$3.8 \times 10^{-12}$
132	$3.5 \times 10^{-8}$	$2.7 \times 10^{-10}$
135	$4 \times 10^{-8}$	$1.2 \times 10^{-9}$